Varenicline adjunctive treatment in schizophrenia.

Trial Profile

Varenicline adjunctive treatment in schizophrenia.

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Dec 2017

At a glance

  • Drugs Varenicline (Primary)
  • Indications Psychotic disorders; Schizoaffective disorder; Schizophrenia
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 19 Mar 2012 Planned end date changed from 1 Jan 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 17 Aug 2011 Status changed from active, no longer recruiting to completed.
    • 07 Sep 2010 Planned end date changed from 1 Jun 2010 to 1 Jan 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top